Body metrics are associated with clinical, free-living, and self-report measures of mobility in a cohort of adults with obesity and multiple sclerosis.

Autor: Cozart JS; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA; Department of Psychology, University of Missouri-Kansas City, Kansas City, Missouri, USA. Electronic address: jsp3b@mail.umkc.edu., Bruce AS; Center for Children's Healthy Lifestyles and Nutrition, Children's Mercy Hospital, Kansas City, Missouri, USA; Department of Pediatrics, University of Kansas Medical Center, Kansas City, Kansas, USA., Shook RP; Center for Children's Healthy Lifestyles and Nutrition, Children's Mercy Hospital, Kansas City, Missouri, USA; Department of Pediatrics, Children's Mercy Hospital, Kansas City, Missouri, USA; School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri USA., Befort C; Department of Population Health, University Kansas Medical Center, Kansas City, Kansas, USA., Siengsukon C; Department of Physical Therapy, Rehabilitation Science, and Athletic Training, University of Kansas Medical Center, Kansas City, Kansas, USA., Simon S; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA., Lynch SG; Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA., Mahmoud R; Department of Neurology, Saint Luke's Hospital, Kansas City, Missouri, USA; Department of Neurology, University of Missouri-Kansas City, Kansas City, Missouri, USA., Drees B; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA; Department of Internal Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, Missouri, USA; Graduate School of the Stowers Institute for Medical Research, Kansas City, Missouri, USA., Posson P; Center for Children's Healthy Lifestyles and Nutrition, Children's Mercy Hospital, Kansas City, Missouri, USA., Hibbing PR; Department of Kinesiology & Nutrition, University of Illinois Chicago, Chicago, Illinois, USA., Huebner J; Department of Community and Family Medicine University Health Lakewood Medical Center, Medicine, Kansas City, Missouri, USA., Bradish T; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA., Robichaud J; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA., Bruce JM; Department of Biomedical and Health Informatics, University of Missouri-Kansas City, School of Medicine, Kansas City, Missouri, USA; Departments of Neurology and Psychiatry, University Health, Kansas City, Missouri, USA.
Jazyk: angličtina
Zdroj: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2023 Nov; Vol. 79, pp. 105010. Date of Electronic Publication: 2023 Sep 15.
DOI: 10.1016/j.msard.2023.105010
Abstrakt: Background: Obesity is associated with multiple sclerosis (MS) onset and may contribute to more rapid disability accumulation. Whether obesity impacts mobility in MS is uncertain. Some studies find that obesity in MS is associated with poorer mobility; other studies find no relationship. Discrepant findings may be due to differences in measurement and methodology. In the present study, we employ a comprehensive battery of anthropometric and mobility measures in a sample of people with MS and obesity.
Methods: Participants with MS (N = 74) completed a battery of adiposity measurements (weight, height, waist circumference, and full body dual-energy x-ray absorptiometry [DXA] scans). They also completed validated clinical, free-living (accelerometry), and self-report measures of mobility. Spearman's Rho correlations were used to examine the associations between mobility and obesity measures with Benjamini and Hochberg correction for multiple comparisons. Multiple linear regression was used to examine if adiposity predicted mobility outcomes in people with MS when controlling for age and disease duration.
Results: The majority of participants (n = 70) were diagnosed with relapsing-remitting MS and reported mild MS-related disability on the Patient Determined Disease Steps (M = 0.77, SD = 1.1). Median BMI was 35.8 (SD = 5.4). Higher percentage body fat (measured via DXA) was associated with poorer self-reported physical functioning (r s  = -0.52, p <0.001), less moderate-to-vigorous physical activity (r s  = -0.24, p = 0.04), and worse performance on the Six Minute Walk Test (6MWT; r s  = -0.44, p <0.001), the Timed 25 Foot Walk (T25FW; r s  = 0.45, p <0.001), and the Timed Up and Go test (TUG; r s  = 0.35, p = .003). Higher BMI and waist-to-height ratio (WtHR) were associated with worse outcomes on the 6MWT (BMI; r s  = -0.35, p <0.01, WtHR; r s  = -0.43, p <0.001), T25FW (BMI; r s  = 0.32, p <0.01, WtHR; r s  = 0.38, p <0.001), and the SF-36 (BMI; r s  = -0.29, p <0.005, WtHR; r s  = -0.31, p <0.05). Percentage body fat accounted for an additional 17 % of the variance in the T25FW and 6MWT performance, after controlling for age and disease duration.
Conclusion: Higher BMI, WtHR, and percentage body fat were associated with lower levels of mobility (T25FW and 6MWT) in people with MS who have class I, class II, and class III obesity. Higher percentage body fat was associated with significantly worse performance on clinical, free-living, and self-report measures of mobility in people with MS even when accounting for participant age and disease duration. These findings suggest that people with MS and obesity may show improved mobility with weight loss.
Competing Interests: Declaration of Competing Interest The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jared Bruce is a part-time employee of the National Hockey League, a grantee of the National Multiple Sclerosis Society, has received grant funding from Genzyme, and has received consulting fees from Med IQ. Sharon Lynch has participated in multi-center clinical trials in MS funded by Biogen, Genzyme, Teva, Sanofi, Novartis, Celgene, Roche, Immunic, NIH, NMSS, PCORI, Anokion, TG Therapeutics, and Actelion. Rola Mahmoud participated in clinical trials funded by Biogen and Sanofi Genzyme, served as a speaker for Biogen and consultant /advisory board for Horizon, Genentech and Sanofi Genzyme. Catherine Siengsukon is the owner and CEO of Sleep Health Education, LLC. All other authors have nothing to disclose relevant to the current manuscript.
(Copyright © 2023. Published by Elsevier B.V.)
Databáze: MEDLINE